Clinical trial No longer in our active list Phase 3 Interventional Ages 2 to 65

Investigating LP352 for treating seizures in children and adults with developmental and epileptic encephalopathies

Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathies

Run by Longboard Pharmaceuticals · NCT06719141 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new medication called LP352 to see if it can help reduce seizures in children and adults with developmental and epileptic encephalopathies like Lennox-Gastaut Syndrome.

More Epileptic Encephalopathy trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages2 Years to 65 Years
SexAll
Enrollment320 (estimated)
SponsorLongboard Pharmaceuticals
Industry-sponsored
Locations109 sites (Little Rock, Arkansas and 108 other locations)
Trial IDNCT06719141 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include children and adults diagnosed with Lennox-Gastaut Syndrome or other forms of developmental and epileptic encephalopathies who meet specific seizure onset and EEG criteria.

Probably not a fit

Patients who do not have developmental and epileptic encephalopathies or those whose seizures do not meet the study's inclusion criteria may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study, known as the DEEp OCEAN Study, is a double-blind, randomized, placebo-controlled, multicenter investigation aimed at evaluating the efficacy, safety, and tolerability of LP352 in managing seizures associated with developmental and epileptic encephalopathies (DEE). Participants will undergo a structured process that includes screening, a titration period, a maintenance phase, and a taper period, with the entire study lasting approximately 24 months. The study specifically targets individuals with Lennox-Gastaut Syndrome and other forms of DEE, focusing on their unique seizure profiles and developmental challenges.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients suffering from severe seizures associated with developmental and epileptic encephalopathies.

How similar studies have gone: Other studies investigating treatments for Lennox-Gastaut Syndrome and related conditions have shown promise, indicating that this approach may be beneficial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants who are characterized as having Lennox-Gastaut Syndrome (LGS) must fulfill all of the following criteria:

  * Onset of seizures at ≤8 years old
  * History of tonic/tonic-atonic seizures plus at least 1 of the following seizure type(s): atypical absence, atonic, myoclonic, focal impaired awareness, generalized tonic-clonic, nonconvulsive status epilepticus, or epileptic spasms
  * Presence of developmental plateauing or regression
  * History of electroencephalogram (EEG) showing generalized slow (\<2.5 Hertz \[Hz\]) spike-and-wave complexes
* Participants who are characterized as having DEE (Other) must fulfill all of the following criteria:

  * Does not meet criteria for LGS
  * Onset of seizures at ≤5 years old
  * Presence of developmental plateauing or regression
  * History of multiple seizure types
  * History of interictal EEG background showing diffuse or multifocal slowing (with or without epileptiform activity)
* The participant has a current occurrence of at least 1 of the following countable motor seizure types: generalized tonic-clonic, tonic (bilateral), clonic (bilateral), atonic (bilateral) with truncal/leg involvement, focal motor (including hemiclonic), and focal to bilateral tonic-clonic.
* The participant has demonstrated an average of at least 4 countable motor seizures per month for each of the 3 months prior to Screening.
* The participant has been taking 1 to 4 antiseizure medications (ASMs) at a stable dose for at least 4 weeks prior to Screening.
* The participant, parent, or caregiver is willing and able (in the judgment of the investigator) to comply with completion of the diaries throughout the study.
* The participant must be willing and able to provide written informed consent; in instances where the participant is unable to provide consent, an appropriate legal representative.

Exclusion Criteria:

* The participant has a diagnosis of Dravet Syndrome (DS) or has a mutation of the Sodium channel protein type 1 subunit alpha (SCN1A) gene consistent with DS.
* The participant has been admitted to a medical facility for treatment of status epilepticus requiring mechanical ventilation within 3 months prior to Screening.
* The participant has a neurodegenerative disorder as indicated by magnetic resonance imaging or genetic testing.
* The participant has an acquired lesion/injury unrelated to the primary etiology that could contribute as a secondary cause of seizures.
* The participant is receiving exclusionary medications.
* The participant is currently using any cannabis product or cannabidiol that is not in oral solution/capsule/tablet form, not obtained from a government-approved dispensary, or contains ≥50% Delta-9-tetrahydrocannabinol (THC).
* The participant has unstable, clinically significant neurologic (other than the disease being studied; eg, recurrent strokes), psychiatric, cardiovascular (eg, pulmonary arterial hypertension, cardiac valvulopathy, orthostatic hypotension/tachycardia), pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or endocrine disease or other abnormality which may impact the ability of the participant to participate or potentially confound the study results.
* The participant is unable or unwilling to comply with any of the study requirements or timelines.

Where it's running

  • Arkansas Children's Hospital - PIN
    Little Rock, Arkansas, United States
    Recruiting
  • Children's Hospital Los Angeles - PIN
    Los Angeles, California, United States
    Recruiting
  • David Geffen School of Medicine at UCLA
    Los Angeles, California, United States
    Recruiting
  • The Stanford Division of Child Neurology
    Palo Alto, California, United States
    Recruiting
  • UCSF Children's Hospital
    San Francisco, California, United States
    Recruiting
  • Children's Hospital Colorado.
    Aurora, Colorado, United States
    Recruiting
Show 44 more locations
  • Children's National Medical Center
    Washington D.C., District of Columbia, United States
    Recruiting
  • NW FL Clinical Research Group, LLC
    Gulf Breeze, Florida, United States
    Recruiting
  • University of Miami - 1120 NW 14th St
    Miami, Florida, United States
    Recruiting
  • Nicklaus Children's Hospital - PIN
    Miami, Florida, United States
    Recruiting
  • University of South Florida - 2 Tampa General Circle
    Tampa, Florida, United States
    Recruiting
  • Pediatric Epilepsy and Neurology Specialists
    Tampa, Florida, United States
    Recruiting
  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics - PIN
    Atlanta, Georgia, United States
    Recruiting
  • Consultants In Epilepsy and Neurology PLLC
    Boise, Idaho, United States
    Recruiting
  • Ann and Robert H Lurie Childrens Hospital of Chicago - PIN
    Chicago, Illinois, United States
    Recruiting
  • University of Iowa Hospitals & Clinics - (CRS)
    Iowa City, Iowa, United States
    Recruiting
  • Mid-Atlantic Epilepsy and Sleep Center
    Bethesda, Maryland, United States
    Recruiting
  • Massachusetts General Hospital - 175 Cambridge St
    Boston, Massachusetts, United States
    Recruiting
  • Mayo Clinic - PIN
    Rochester, Minnesota, United States
    Recruiting
  • Institute of Neurology and Neurosurgery at Saint Barnabas, LLC
    Livingston, New Jersey, United States
    Recruiting
  • Northeast Regional Epilepsy Group - Morristown - 310 Madison Ave
    Morristown, New Jersey, United States
    Recruiting
  • NYU Comprehensive Epilepsy Center - BRANY - PPDS
    New York, New York, United States
    Recruiting
  • Oregon Health and Science University
    Portland, Oregon, United States
    Recruiting
  • Le Bonheur Childrens Outpatient Center - PIN
    Memphis, Tennessee, United States
    Recruiting
  • Child Neurology Consultants of Austin - 6811 Austin Center Blvd
    Austin, Texas, United States
    Recruiting
  • Cook Children's Jane and John Justin Neurosciences Center - PIN
    Fort Worth, Texas, United States
    Recruiting
  • The University of Texas Medical School at Houston
    Houston, Texas, United States
    Recruiting
  • Multicare Health System - Mary Bridge Pediatrics
    Tacoma, Washington, United States
    Recruiting
  • Prince of Wales Hospital
    Randwick, New South Wales, Australia
    Recruiting
  • Sydney Children's Hospital
    Randwick, New South Wales, Australia
    Recruiting
  • Children's Hospital at Westmead
    Westmead, New South Wales, Australia
    Recruiting
  • Royal Brisbane & Women's Hospital
    Herston, Queensland, Australia
    Recruiting
  • Queensland Children's Hospital
    South Brisbane, Queensland, Australia
    Recruiting
  • Austin Hospital
    Heidelberg, Victoria, Australia
    Recruiting
  • Royal Children's Hospital Melbourne
    Parkville, Victoria, Australia
    Recruiting
  • The Alfred Hospital
    Melbourne, Australia
    Recruiting
  • UZ Antwerpen
    Edegem, Antwerpen, Belgium
    Recruiting
  • UZ Leuven - PPDS
    Leuven, Belgium
    Recruiting
  • Instituto de Neurologia de Curitiba (INC)
    Curitiba, Paraná, Brazil
    Recruiting
  • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP - PPDS
    Ribeirão Preto, São Paulo, Brazil
    Recruiting
  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
    São José do Rio Preto, São Paulo, Brazil
    Recruiting
  • Instituto de Psiquiatria HC FMUSP
    São Paulo, Brazil
    Recruiting
  • Children's and Women's Health Centre of British Columbia-4480 Oak St
    Vancouver, British Columbia, Canada
    Recruiting
  • London Health Sciences Centre -800 Commissioners Rd E
    London, Ontario, Canada
    Recruiting
  • Peking University First Hospital - Daxing Campus
    Beijing, Beijing Municipality, China
    Recruiting
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Recruiting
  • Shenzhen Children's Hospital
    Shenzhen, Guangdong, China
    Recruiting
  • Wuhan Children's Hospital
    Wuhan, Hubei, China
    Recruiting
  • Children's Hospital of Fudan University
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Beijing Children's Hospital, Capital Medical University - PIN
    Beijing, China
    Recruiting

+59 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Understanding Developmental and Epileptic Encephalopathy through Clinical Data

    This study is trying to gather and analyze health information from patients with Developmental and Epileptic Encephalopathy to better understand the condition and improve treatment options.

    Recruiting Imagine Institute · Amiens and 22 other locations · NCT06380192

  • Understanding Pyrimidine and Purine Metabolism Disorders

    This study is trying to learn more about pyrimidine and purine metabolism disorders by comparing affected people with their healthy family members to see what factors might influence their condition.

    Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06092346

  • Multi-biomarkers in DEE: a big look at genetic epilepsies

    This study tests a panel of multi-omic biomarkers in people with genetically confirmed Developmental and Epileptic Encephalopathy to help understand prognosis and potential biomarkers for future therapies.

    Recruiting at 14 sites Istituto Giannina Gaslini · Antwerp and 13 other locations · NCT07909382

  • SLC6A1-NDD: A Longitudinal Look at How the Disorder Progresses

    This study follows children and young people with SLC6A1-NDD over two years to see how the condition changes over time and to test which assessments work for future research.

    Recruiting at 3 sites UCB Pharma · New York, New York and 2 other locations · NCT07531511

  • S230815 for children with KCNT1-related developmental and epileptic encephalopathy

    This study will test whether the investigational medicine S230815 is safe, well tolerated, and affects seizures and related symptoms in children aged 2–12 who have KCNT1-related developmental and epileptic encephalopathy.

    Recruiting at 11 sites Phase 1/2 Servier · Orange, California and 14 other locations · NCT07227857

  • Elsunersen treatment for infants with early-onset SCN2A-related epileptic encephalopathy

    This trial tests whether elsunersen can reduce seizures and is safe in infants and young children with early-onset SCN2A-related developmental and epileptic encephalopathy who have gain-of-function variants.

    Recruiting at 8 sites Phase 3 Praxis Precision Medicines · San Diego, California and 9 other locations · NCT07019922

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.